Gaucher disease: resetting the clinical and scientific agenda.
Mistry
Pramod K
PK
Weinreb
Neal J
NJ
Brady
Roscoe O
RO
Grabowski
Gregory A
GA
D000328:Adult; D002648:Child; D005776:Gaucher Disease / Q000150:complications / Q000188:drug therapy* / Q000201:enzymology / Q000208:ethnology / Q000235:genetics / Q000276:immunology; D018740:Genetic Heterogeneity; D020022:Genetic Predisposition to Disease; D005962:Glucosylceramidase / Q000008:administration & dosage / Q000009:adverse effects* / Q000172:deficiency / Q000235:genetics / Q000627:therapeutic use; D005963:Glucosylceramides / Q000097:blood; D006801:Humans; D006976:Hypertension, Pulmonary / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology; D007585:Jews / Q000235:genetics; D018448:Models, Immunological; D009101:Multiple Myeloma / Q000453:epidemiology / Q000209:etiology / Q000235:genetics; D009154:Mutation; D009369:Neoplasms / Q000139:chemically induced / Q000453:epidemiology / Q000209:etiology* / Q000235:genetics; D015995:Prevalence; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D012042:Registries / Q000706:statistics & numerical data; D012306:Risk; D012641:Selection, Genetic; D019564:Unnecessary Procedures
D005963:Glucosylceramides; D011994:Recombinant Proteins; D005962:Glucosylceramidase; C090568:imiglucerase